JY
NGM

Jeff Yass’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Jeff Yass’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,900
Closed -$143K – 14071
2022
Q3 		$143K Buy
+10,900
New +$165K ﹤0.01% 11310

Other funds holding NGM

CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jeff Yass's NGM Position: Q1 2024 in Review

Jeff Yass sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 35,092 shares — an estimated $30.1K sold.

Jeff Yass first reported a position in NGM in Q1 2020 and held it in 11 quarters. The position peaked at $416K in Q4 2020. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Jeff Yass reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Jeff Yass sold 35,092 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $30.1K.
  • Jeff Yass first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
  • Jeff Yass's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $416K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.